Shanghai Allist Pharmaceuticals (688578) Q1 2025 earnings summary

Executive summary

• Revenue reached RMB 1.10 billion, up 47.86% year-over-year, driven by strong sales of core oncology products.

• Net profit attributable to shareholders was RMB 410 million, a 34.13% increase year-over-year.

• R&D investment rose 74.86% year-over-year, supporting clinical advancement of in-house and in-licensed drugs.

• Commercialization of core products, especially Furmetinib, continued to expand market share and patient reach.

• New clinical trials initiated, including a global Phase III study for non-classical EGFR mutation NSCLC.

Financial highlights

• Operating income: RMB 1,098 million, up 47.86% year-over-year.

• Net profit: RMB 410 million, up 34.13% year-over-year.

• Basic and diluted EPS: RMB 0.91, up 33.82% year-over-year.

• Operating cash flow: RMB 393 million, up 7.54% year-over-year.

• Total assets: RMB 6.23 billion, up 5.38% from year-end 2024.

Outlook and guidance

• Continued focus on expanding commercialization of oncology drugs and advancing clinical pipeline.

• Ongoing investment in R&D to address unmet clinical needs and develop first-in-class and best-in-class therapies.